An update is available for this article. Background: The prevalence of osteoporosis is
increasing in the United States. Purpose: To evaluate low bone mass and osteoporosis …

Osteoporosis is a worldwide disease characterized by reduction of bone mass and alteration
of bone architecture resulting in increased bone fragility and increased fracture risk. Causes …

An update is available for this article. Description: This guideline updates the 2017 American
College of Physicians (ACP) recommendations on pharmacologic treatment of primary …

Objective The objective is to formulate clinical practice guidelines for the pharmacological
management of osteoporosis in postmenopausal women. Conclusions Evidence from …

Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures.
Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the …

Background This study evaluated the risk of long-term analgesic use after low-risk surgery in
older adults not previously prescribed analgesics. Methods We conducted a retrospective …

Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal
women with osteoporosis. To investigate long‐term effects of ZOL on bone mineral density …

Advances in hematopoietic cell transplantation (HCT) technology and supportive care
techniques have led to improvements in long-term survival after HCT. Emerging indications …

Bisphosphonates reduce the rate of osteoporotic fractures in clinical trials and community
practice.“Atypical” nontraumatic fractures of the diaphyseal (subtrochanteric or shaft) part of …

Background: Osteoporosis is a major contributor to the propensity to fracture among older
adults, and various pharmaceuticals are available to treat it. Purpose: To update a review …